CN1045383C - Medicine composite for curing senile cataract - Google Patents
Medicine composite for curing senile cataract Download PDFInfo
- Publication number
- CN1045383C CN1045383C CN93103957A CN93103957A CN1045383C CN 1045383 C CN1045383 C CN 1045383C CN 93103957 A CN93103957 A CN 93103957A CN 93103957 A CN93103957 A CN 93103957A CN 1045383 C CN1045383 C CN 1045383C
- Authority
- CN
- China
- Prior art keywords
- present
- pharmaceutical composition
- senile cataract
- cataract
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002177 Cataract Diseases 0.000 title claims abstract description 21
- 201000008525 senile cataract Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 5
- 239000002131 composite material Substances 0.000 title description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 3
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 3
- 239000011718 vitamin C Substances 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000011780 sodium chloride Substances 0.000 abstract description 5
- 235000002639 sodium chloride Nutrition 0.000 abstract description 5
- 235000011164 potassium chloride Nutrition 0.000 abstract description 4
- 239000001103 potassium chloride Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000004438 eyesight Effects 0.000 description 13
- 230000035807 sensation Effects 0.000 description 5
- 210000000695 crystalline len Anatomy 0.000 description 4
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000818 Catalin Polymers 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a medicine composition for treating senile cataracts. The present invention has favorable curative effects on treating senile cataracts. The present invention comprises NaCl, KCl, vitamin C, sodium bicarbonate and medicinal carrier liquid which is usually adopted in the technical field of medicines. The present invention also relates to a method for treating senile cataracts.
Description
The present invention relates to be used for the treatment of the pharmaceutical composition of senile cataract.
Known cataract is the one of the main reasons that the people is lost one's sight, and at present, the blind number in the whole world is about forty-two million, and wherein having about 1,700 ten thousand people is because of losing one's sight that cataract causes.In cataract patient, occupy most ratios among senile cataract (Senile CatarctSC) patient.The also illogical at present understanding of relevant cataractous pathogenesis, but it is believed that cataract is relevant with albumen, lipid, vitamin, micronutrient levels variation in crystal and the aqueous humor.Treatment for senile cataract has Drug therapy, as present widely used catalin, Bai Keming, fine can be bright, method gram Lijin, Phaeolin etc., and operative treatment, but these medicines can only stop PD, and operative treatment, because the senile cataract patient age is all bigger, and often with other disease, as hypertension, heart disease, therefore, operative treatment has certain risk for senile white interior patient.Therefore, to have the medicine of treatment senile cataract of better curative effect be very necessary in exploitation.
The objective of the invention is to seek the medicine of treatment senile cataract with better curative effect.
The present inventor thinks that SC patient's pathogenesis is: the eye malnutrition, in the cell, outer liquid deficiency, eye metabolism and blood circulation generation obstacle cause the ophthalmic crystal thing to reduce, the colloid thing increases, osmotic pressure diminishes, and crystalline lens produces hydration simultaneously, causes the starvation of cell to the inorganic salt and other material demand itself, cavity increases, finally make lens fibersization and muddy, lenticular power is destroyed, visual deterioration.Therefore, treat senile cataract, just need improve the partial body fluid of eyes and regulate, and by the eye electrolyte disturbance, the eye malfunction that nutritional status lowly causes improve its metabolism ability, keep and strengthen the crystalline lens transparency.The present inventor is through extensively and profoundly research, unexpectedly found a kind of pharmaceutical composition, it has regulates and additional ophthalmic and ambient body fluid, promote the colloid thing to decompose, strengthen the effect of crystalline lens transparency, thereby each phase (initial phase, immature phase and period of maturation) SC patient's vision is improved.Based on above-mentioned discovery, the present inventor has finished the present invention.
According to the present invention, pharmaceutical composition of the present invention contains liquid-carrier commonly used in sodium chloride, potassium chloride, vitamin C, sodium bicarbonate and the pharmaceutical field.Will be specifically, pharmaceutical composition of the present invention is made into liquid drops, and its PH is 7.0.Say that more specifically every 100ml pharmaceutical composition of the present invention contains 0.82-0.97g NaCl, 0.038-0.048gKCl, 0.08-0.2gVC, 0.007-0.015 NaHCO
3
According to the present invention, pharmaceutical composition of the present invention uses with the drop form.
The present invention also comprises the method for the treatment of SC, and it comprises pharmaceutical composition of the present invention with the drop form administration in SC patient.Using dosage is generally: every day 4-5 time, each: 1-2 drips.Concrete using dosage depends on patient's severity extent.
According to the present invention, pharmaceutical composition of the present invention not only can stop SC patient's the state of an illness to further develop, and can improve SC patient's vision.Pharmaceutical composition avirulence of the present invention.
The present invention implements by following preparation and treats real: execute example and further specify.But these embodiment do not mean that this is to any restriction of the present invention.
Embodiment one
Pharmaceutical formulation: component content (weight %)
NaCl 0.9
KCl 0.042
NaHCO
3?0.013
Vc 0.8
Additive 0.4
Distilled water adds to 100
With mode known in the art with NaCl, KCl, NaHCO
3, VC, additive and distilled water be made into 100ml solution, sterilization then.
Embodiment two
Patient's sex: the man, the age: 61, two naked visions are 0.4, and clinical diagnosis is the senile cataract initial stage, use medicine composite for curing of the present invention, 4 times/day each two, treat after 16 days, two eye visions are respectively OD 1.0, and OS 1.2 continues treatment 20 days, and two eye visions all reach 1.5.Through ophthalmofundoscopy, the lenticular opacity position all absorbs, and consolidates the medication two weeks.Drug withdrawal is checked after half a year, and binocular vision is 1.5.
Embodiment three
Patient's sex: the man, the age: 71, naked vision OU 0.3, clinical diagnosis is the underdone phase of senile cataract.Use medicine composite for curing of the present invention, 4 times/day each 2, treated 10 days, have an eyesight test, binocular vision is 0.4, treats 20 days, has an eyesight test, binocular vision is 0.5, the treatment to 45 days, have an eyesight test, binocular vision is 0.6
Embodiment four
Patient's sex: the man, the age: 76, medication checks that eyes have only light sensation/0.5m, clinical diagnosis is the senile cataract period of maturation.Treat with pharmaceutical composition of the present invention, 5 times/day, each 2, treated 57 days, check eyes, OD light sensation/2m then, OS light sensation/2.5m, treatment checked to 74 days, eyes light sensation/5m then, light sensation increases 4.5m altogether.
Above embodiment shows that pharmaceutical composition of the present invention has good treatment senile cataract effect.
Claims (4)
1 is used for the treatment of the pharmaceutical composition of senile cataract, and wherein every this pharmaceutical composition of 100ml contains 0.82-0.97gNaCL,
0.038-0.048gKCL, 0.08-0.2g vitamin C, 0.007-0.015g sodium bicarbonate.
The pharmaceutical composition of 2 claim 1, wherein this pharmaceutical composition is a liquid.
The pharmaceutical composition of 3 claim 1, wherein this pharmaceutical composition uses with the drop form.
The pharmaceutical composition of 4 claim 1, wherein the pH value of this pharmaceutical composition is 7.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103957A CN1045383C (en) | 1993-04-07 | 1993-04-07 | Medicine composite for curing senile cataract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103957A CN1045383C (en) | 1993-04-07 | 1993-04-07 | Medicine composite for curing senile cataract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1093259A CN1093259A (en) | 1994-10-12 |
| CN1045383C true CN1045383C (en) | 1999-10-06 |
Family
ID=4984930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93103957A Expired - Fee Related CN1045383C (en) | 1993-04-07 | 1993-04-07 | Medicine composite for curing senile cataract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1045383C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075430A1 (en) * | 2009-12-14 | 2011-06-23 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| TWI535461B (en) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | Colon cleansing solution, composition for preparing the solution, kit comprising the composition or solution, and method of preparing the same |
| LT2895163T (en) | 2012-09-11 | 2019-06-25 | Norgine Bv | Compositions comprising peg and ascorbate |
| AU2014236582B2 (en) | 2013-03-14 | 2018-03-29 | The University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| WO2017083619A1 (en) | 2015-11-13 | 2017-05-18 | The University Of Massachusetts | Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4620979A (en) * | 1985-08-02 | 1986-11-04 | Schachar Ronald A | Ophthalmological irrigating solution containing ascorbate |
| EP0205279A1 (en) * | 1985-05-29 | 1986-12-17 | Eye Research Institute Of Retina Foundation | Non-toxic ophthalmic preparations and methods of preparing them |
-
1993
- 1993-04-07 CN CN93103957A patent/CN1045383C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0205279A1 (en) * | 1985-05-29 | 1986-12-17 | Eye Research Institute Of Retina Foundation | Non-toxic ophthalmic preparations and methods of preparing them |
| US4911933A (en) * | 1985-05-29 | 1990-03-27 | Eye Research Institute Of Retina Foundation | Non-toxic opthalmic preparations |
| US4620979A (en) * | 1985-08-02 | 1986-11-04 | Schachar Ronald A | Ophthalmological irrigating solution containing ascorbate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1093259A (en) | 1994-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McCaa | The eye and visual nervous system: anatomy, physiology and toxicology | |
| CN103860625A (en) | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof | |
| CN1045383C (en) | Medicine composite for curing senile cataract | |
| CN108125996A (en) | It is a kind of for visual fatigue, dry eyes eye-drops preparations | |
| WO2013043832A1 (en) | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion | |
| EA017752B1 (en) | Use of l-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal disease | |
| CN109288738A (en) | Eye protection composition, eye mask and preparation method thereof | |
| RU2076671C1 (en) | Solution for protection and treatment of cornea sickness and damage | |
| CN109260136A (en) | Eye-protecting cream and preparation method thereof | |
| CN1103220C (en) | Medicinal composition for treating optical atrophy | |
| RU2106843C1 (en) | Method to treat myopia | |
| CN1899304A (en) | Eye drops for cataract and its preparing method | |
| RU2512801C1 (en) | Therapeutic eye balsam | |
| CN1927392A (en) | Composite collagen eye drops | |
| JPS5857319A (en) | High-viscosity hyaluronic acid preparation | |
| RU2128975C1 (en) | Ophthalmic drops "balarpan" | |
| IL306146A (en) | Water-soluble topical ophthalmic preparation containing lutein and production method thereof | |
| RU2460502C1 (en) | Method of treating beginning age cataract | |
| CN1128656A (en) | Application of anisodamine for prepn. of eye drops for curing pyopia | |
| CN103860731A (en) | Pure traditional Chinese medicine preparation for treating eye disease | |
| CN100362991C (en) | Medicine composition for ophthalmology department | |
| CN107802597A (en) | A kind of sodium hyaluronate composition and its preparation method and application | |
| RU2216331C1 (en) | Ophthalmic drops | |
| RU2140236C1 (en) | Method of treatment of patients with diabetic retinopathy | |
| RU2259833C1 (en) | Pharmaceutical composition for treating inflammatory diseases and eye cornea injuries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |